Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | AR | P10275 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.36 |
| ▸ | RXRA | P19793 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5963769 | 0.84 | PDE7B (0.39) | SLC6A4SLC6A3TP53SLC6A2PDE7A | |
| SCHEMBL5964235 | 0.84 | SMN1; SMN2 (0.48) | SMN1; SMN2MEN1KMT2ASLC6A4SLC6A3 | |
| SCHEMBL5963932 | 0.83 | KMT2A (0.40) | KMT2APOLBPDE7A | |
| SCHEMBL5963733 | 0.81 | PDE7A (0.41) | KMT2ASLC6A4SLC6A3POLBSLC6A2 | |
| SCHEMBL5963527 | 0.79 | ALDH1A1 (0.42) | SMN1; SMN2MEN1KMT2ASLC6A4SLC6A3 | |
| SCHEMBL5963585 | 0.79 | POLB (0.42) | MEN1KMT2AHTTPOLB | |
| SCHEMBL5963924 | 0.78 | SMN1; SMN2 (0.39) | SMN1; SMN2MEN1KMT2ASLC6A4SLC6A3 | |
| SCHEMBL5964630 | 0.78 | SMN1; SMN2 (0.41) | SMN1; SMN2MEN1KMT2ASLC6A4SLC6A3 | |
| SCHEMBL5963591 | 0.78 | SLC6A4 (0.43) | KMT2ASLC6A4SLC6A3SLC6A2PDE7A | |
| SCHEMBL5963658 | 0.77 | AKR1B1 (0.40) | KMT2APDE7A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7125840-B2 | Substituted dipeptides as growth hormone secretagogues | ELI LILLY AND COMPANY (US) | 2006-10-24 | — | — | US | disclosed |
| EP-1326851-B1 | SUBSTITUTED DIPEPTIDES AS GROWTH HORMONE SECRETAGOGUES | LILLY CO ELI (US) | 2004-06-30 | — | — | EP | disclosed |
| US-20040058971-A1 | Substituted dipeptides as growth hormone secretagogues | ELI LILLY AND COMPANY | 2004-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040058971-A1 | Substituted dipeptides as growth hormone secretagogues | GHSR, GHRHR, SSTR4 | SMN1; SMN2 3213/4885MEN1 136/4885KMT2A 3557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.